See more : Victoria Gold Corp. (VGCX.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nissin Foods Holdings Co.,Ltd. (2897.T) Income Statement Analysis – Financial Results
- Leader Education Limited (1449.HK) Income Statement Analysis – Financial Results
- Avanti Helium Corp. (AVN.V) Income Statement Analysis – Financial Results
- Blue Gem Enterprise (BGEM) Income Statement Analysis – Financial Results
- Sichuan Xichang Electric Power Co.,Ltd. (600505.SS) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
| General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
| Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
| Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
| EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
| EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
| Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
| Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
| Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
| Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
| Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.20 | 0.00 | 0.00 |
| EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
| Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
Mindset Pharma strengthens IP portfolio with new provisional patent application
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has announced the filing of a new provisional patent application covering new chemical entities (NCEs) that expand the company's next-generation DMT and 5-MeO-DMT, or 'Family 4', platform, currently under development. The company said the new patent...
Mindset Pharma to Participate in Upcoming Conferences in April 2022
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Mindset Pharma CEO James Lanthier says company pursuing development partners to support clinical process
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier, issued a letter to shareholders to highligh its current partnership with the McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharma companies, and the company's clinical strategy and...
Mindset Pharma identifies new pharmacological insights of first-generation psychedelics through its COPE program with InterVivo Solutions
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has announced that, under its Co-operative Psychedelics Evaluation Platform (COPE) program with InterVivo Solutions Inc, it has identified new pharmacological insights related to the mechanisms of action and bioavailability of 5-MeO-DMT and other first-generation psychedelics....
Mindset Pharma appoints Dr Fiona Randall as senior vice president of external alliance and scientific strategy
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) welcomed Dr Fiona Randall as its senior vice president of external alliances and scientific strategy. “We have a tremendous opportunity to accelerate Mindset's growth through strategic partnerships.
Mindset Pharma identifies additional drug candidates from 'Family 3' compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug candidates, and will initiate proof of concept preclinical studies to further measure the viability of these compounds as daily pro-cognitive...
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
Mind Medicine (NASDAQ:MNMD) shares closed up 25.48% at $1.17 Mindset Pharma (OTC:MSSTF) shares closed up 15.85% at $0.47
Mindset Pharma enters manufacturing deal with leading CDMO for next-generation psilocybin drug candidate, MSP-1014
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has entered into a pharmaceutical manufacturing agreement with a leading contract development and manufacturing organization (CDMO) for the production of pharmaceutical-grade batches of Mindset's next-generation psilocybin drug candidate, MSP-1014. Following a co-development partnership...
Mindset Pharma Teams Up With The McQuade Center To Develop 2 Families Of Novel Psychedelic Compounds
This article was originally published on Psychedelic Spotlight and appears here with permission. It's yet another sign that the pharmaceutical industry at large is taking the potential of psychedelics very seriously.
Stifel GMP encouraged by US$5M investment into Mindset Pharma, which provides "further validation for psychedelic sector"
Stifel GMP said it was encouraged to see the recent investment by The McQuade Center for Strategic Research and Development (MSRD) into Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF), which the broker said, signaled the interest of Big Pharma in the psychedelic...
Source: https://incomestatements.info
Category: Stock Reports